The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network

Giuseppe Luigi Banna 1, Umberto Basso 2, Emilio Francesco Giunta 3, Lucia Fratino 4, Sara Elena Rebuzzi 5,6, Sebastiano Buti 7, Marco Maruzzo 8, Ugo De Giorgi 8, Veronica Murianni 9, Marika Cinausero 10, Helga Lipari 11, Teresa Gamba 12, Orazio Caffo 13, Davide Bimbatti 2, Arianna Dri 10,14, Alessandra Mosca 3, Paola Ermacona 10, Francesca Vignani 12, Aichi Msaki 2, Barbara Bonifacio 10, Valentina Lombardo 11, Vincenza Conteduca 15, Giuseppe Fornarini 9,1 10 and Pasquale Rescigno 3,*,†

Citation: Banna, G.L.; Basso, U.; Giunta, E.F.; Fratino, L.; Rebuzzi, S.E.; Buti, S.; Maruzzo, M.; De Giorgi, U.; Murianni, V.; Cinausero, M.; et al. The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network. Curr. Oncol. 2022, 29, 7745–7753. https://doi.org/10.3390/curroncol29100612

Abstract: Introduction: Androgen receptor pathway inhibitors (ARPIs) have been increasingly offered to older patients with prostate cancer (PC). However, prognostic factors relevant to their outcome with ARPIs are still little investigated. Methods and Materials: The Meet-URO network ADHERE was a prospective multicentre observational cohort study evaluating and monitoring adherence to ARPIs metastatic castrate-resistant PC (mCRPC) patients aged ≥70. Cox regression univariable and multivariable analyses for radiographic progression-free (rPFS) and overall survival (OS) were performed. Unsupervised median values and literature-based thresholds where available were used as cut-offs for quantitative variables. Results: Overall, 234 patients were enrolled with a median age of 78 years (73–82); 86 were treated with abiraterone (ABI) and 148 with enzalutamide (ENZ). With a median follow-up of 15.4 months (mo.), the median rPFS was 26.0 mo. (95% CI, 22.8–29.3) and OS 48.8 mo. (95% CI, 36.8–60.8). At the MVA, independent prognostic factors for both worse rPFS and OS were Geriatric G8 assessment ≥14 (p < 0.001 and p = 0.004) and PSA decline ≥50% (p < 0.001 for both); time to castration resistance ≥31 mo. and setting of treatment (i.e., post-ABI/ENZ) for rPFS only (p < 0.001 and p = 0.01, respectively); age ≥78 years for OS only (p = 0.008). Conclusions: Baseline G8 screening is recommended for mCRPC patients aged ≥70 to optimise ARPIs in vulnerable individuals, including early introduction of palliative care.

Keywords: G8 score; geriatric assessment; adherence to treatment; prostate cancer
1. Introduction

Prostate cancer is the fourth most common cancer worldwide [1]. Age-standardized incidence and mortality are 68 and 10 per 100,000, respectively, in more developed regions [2]. The average age at which prostate cancer (PC) is diagnosed in western populations is 66 years old. However, at the time of diagnosis, 60% of patients are 65 years or older, and by 2040, this percentage will rise to 70% [3]. Nearly 70% of PC deaths occur in men aged ≥75 [1]. While the overall mortality rate is predicted to remain steady, the number of men aged 70 and older who die from prostate cancer will nearly double by 2040 [1]. Furthermore, the median age of men who develop the metastatic disease is considerably older, and the median age of those who die due to prostate cancer is eighty years [4]. Treatment costs for older men with early and late prostate cancer are already high and projected to rise in the following decades [3]. Androgen receptor pathway inhibitors (ARPIs) represent the standard of care for advanced PC (APC). ARPIs are often preferred to intravenous chemotherapy for older patients with metastatic castrate-resistant PC (mCRPC) due to their more favourable toxicity profile and convenient administration [5]. However, treatment choice should not be based on patients’ age but on the overall evaluation of the patients’ health status. The gold standard for health status evaluation of older patients is the Comprehensive Geriatric Assessment (CGA), although it is time-consuming and requires a specialist assessment [6]. The Geriatric G8 (G8) score assesses, with eight questions, the patient’s food intake, weight loss, body mass index, mobility, neuropsychological problems, polypharmacy, self-perceived health status and age. An abnormal G8 score (>14 on a scale from 0 to 17) was strongly associated with mortality in almost a thousand cancer male patients aged ≥70 [7]. We have previously reported that the G8 score is an associated factor with adherence to ARPIs in older mCRPC patients [8–10]. In the current analysis, we investigated the clinical baseline and on-ARPI variables associated with radiographic progression-free survival (rPFS) and overall survival (OS).

2. Methods

The ADHERE was a Meet-URO network prospective multicentre observational study monitoring adherence to abiraterone (ABI) or enzalutamide (ENZ) in patients with mCRPC aged ≥70. To assess the prognostic factors on rPFS and OS, a Cox regression univariable analysis (UVA) was performed, including the following clinical characteristics: baseline prior ARPI start, Gleason score (≥8 vs. <8), surgery on primary (yes vs. no), time to CR (≥31 vs. <31 months [mo.]), baseline at ARPI start, age (≥78 vs. <78), sites of metastases (lymph nodes only vs. bone vs. visceral), setting of therapy (pre- vs. post-chemotherapy vs. post-ABI/ENZ), steroid use (yes vs. no), Charlson comorbidity score (≥10 vs. <10), G8 (≤14 vs. >14), IADL (≤6 vs. >6), number of concomitant therapies (≥3 vs. <3), caregiver presence (yes vs. no); on-ARPI characteristics, type of therapy (ABI vs. ENZ), PSA decline by 50% (PSA50) (yes vs. no), grade 1/2 toxicity (yes vs. no), grade 3/4 toxicity (yes vs. no). The rPFS was defined as the time from ARPI start to date of disease progression on imaging as per RECIST 1.1, or death from any cause, whichever occurred first. OS was calculated from the ARPI start date until death or the last follow-up. Unsupervised median values were used as cut-offs for quantitative variables alongside the literature-reported values of 9 for Charlson comorbidity score [11], <12 months for time to castration resistance (CR) [12] and ≥75 for age. Cox regression multivariable analysis (MVA) was performed for OS and PFS of clinical variables with a p-value < 0.05 at the UVA. When both median and literature-reported cut-off values of quantitative variables were significant, the one with the lowest p-value was carried on in the MVA. Kaplan–Meier curves were used for time-to-event analyses. The analysis was performed using the statistical software SigmaPlot v12.5 (Systat Software, Inc., Dusseldorf, Germany).

3. Results

The characteristics of patients in the overall cohort and the ARPI-relative ones are summarized in Supplementary Table S1. Among the 234 enrolled patients, the median age
of 78 years (73–82); 86 were treated with ABI and 148 with ENZ. With a median follow-up of 15.4 months (mo.) (95% confidence interval [CI], 12.1–18.7), the median rPFS was 26.0 mo. (95% CI, 22.8–29.3) and OS 48.8 mo. (95% CI, 36.8–60.8).

At UVA, age ≥ 78 or ≥ 75 was associated with worse OS (p = 0.004 or p = 0.014) but not shorter rPFS (p = 0.077 or p = 0.090); time to CR < 31 or <12 mo. and Charlson score ≥ 9 were associated with worse rPFS (p = 0.002 or p = 0.007, p = 0.034) but not shorter OS (p = 0.111 or p = 0.168, p = 0.361); while G8 ≤ 14 and lack of biochemical response were both associated with worse OS (p < 0.001 for both) and rPFS (p = 0.032, p < 0.001) (Table 1). Interestingly, presence of a caregiver and treatment with ENZ (vs. ABI) were associated with shorter rPFS (p = 0.047, p = 0.042) (Table 1).

At MVA, independent prognostic factors for both worse rPFS and OS were G8 ≤ 14 (p < 0.001 and p = 0.004) and PSA decline ≥ 50% (p < 0.001 for both); time to castration resistance ≥ 31 mo. and setting of treatment (i.e., post-ABI/ENZ) for rPFS only (p < 0.001 and p = 0.01, respectively); age ≥ 78 years for OS only (p = 0.008).

Conclusions: Baseline G8 screening is recommended for mCRPC patients aged ≥ 70 to optimise ARPIs in vulnerable individuals, including early introduction of palliative care.

Keywords: G8 score; geriatric assessment; adherence to treatment; prostate cancer

Figure 1. Radiographic progression-free survival (rPFS) (A) and overall survival (OS) (B) based on Geriatric G8 with cut-off of 14. Abbreviations: CI, confidence interval; mo., months; NA, not assessable; OS, overall survival; rPFS, radiographic progression-free survival.
| Variable                              | No. (%) | OS HR (95% CI) | p-Value | rPFS HR (95% CI) | p-Value |
|--------------------------------------|---------|----------------|---------|-----------------|---------|
| **Age**, median, years               |         |                |         |                 |         |
| <78                                  | 121 (52)| 1.00 (ref)     |         | 1.00 (ref)      |         |
| ≥78                                  | 113 (48)| 2.51 (1.35–4.6)| 0.004   | 1.42 (0.96–2.10)| 0.077   |
| <75                                  | 84 (36)| 1.00 (ref)     |         | 1.00 (ref)      |         |
| ≥75                                  | 150 (64)| 2.27 (1.77–4.39)| 0.014  | 1.41 (0.95–2.11)| 0.090   |
| **Gleason score**, median            |         |                |         |                 |         |
| <8                                   | 78 (36)| 1.00 (ref)     |         | 1.00 (ref)      |         |
| ≥8                                   | 136 (64)| 1.27 (0.68–2.36)| 0.449  | 1.60 (1.04–2.46)| 0.032   |
| **Surgery at diagnosis**             |         |                |         |                 |         |
| No                                   | 146 (62)| 1.00 (ref)     |         | 1.00 (ref)      |         |
| Yes                                  | 88 (38)| 0.55 (0.30–1.01)| 0.055  | 0.64 (0.43–0.95)| 0.025   |
| **Time to CR**, mo, median           |         |                |         |                 |         |
| ≥31                                  | 118 (50)| 1.00 (ref)     |         | 1.00 (ref)      |         |
| <31                                  | 116 (50)| 1.60 (0.90–2.85)| 0.111  | 1.84 (1.25–2.70)| 0.002   |
| ≥12                                  | 183 (78)| 1.00 (ref)     |         | 1.00 (ref)      |         |
| <12                                  | 51 (22)| 1.57 (0.83–3.00)| 0.168  | 1.76 (1.16–2.66)| 0.007   |
| **Sites of metastases**              |         |                |         |                 |         |
| Bone (non-visceral)                  | 163 (70)| 1.00 (ref)     |         | 1.00 (ref)      |         |
| Lymph nodes (only)                   | 49 (21)| 0.00 (NA)      | 0.997   | 0.31 (0.16–0.62)| <0.001  |
| Visceral                             | 22 (9)| 20.7 (NA)      | 0.428   | 0.80 (0.43–1.49)| 0.488   |
| **Setting of therapy**               |         |                |         |                 |         |
| Post-chemotherapy                    | 57 (24)| 1.00 (ref)     |         | 1.00 (ref)      |         |
| Pre-chemotherapy                     | 162 (69)| 0.78 (0.41–1.50)| 0.350  | 0.79 (0.51–1.23)| 0.300   |
| Post-Abi/Enza                        | 15 (6)| 2.06 (0.45–9.41)| 0.451  | 3.68 (1.57–8.66)| 0.003   |
| **Steroid use**                      |         |                |         |                 |         |
| No                                   | 134 (57)| 1.00 (ref)     |         | 1.00 (ref)      |         |
| Yes                                  | 100 (43)| 1.02 (0.57–1.84)| 0.935  | 0.84 (0.57–1.24)| 0.378   |
| **Charlson score**, median           |         |                |         |                 |         |
| ≥10                                  | 175 (75)| 1.00 (ref)     |         | 1.00 (ref)      |         |
| <10                                  | 59 (25)| 0.99 (0.52–1.89)| 0.977  | 0.96 (0.62–1.47)| 0.846   |
| ≥9                                   | 190 (81)| 1.00 (ref)     |         | 1.00 (ref)      |         |
| <9                                   | 44 (19)| 0.70 (0.32–1.51)| 0.361  | 0.55 (0.32–0.96)| 0.034   |
| **Geriatric G8**, median             |         |                |         |                 |         |
| >14                                  | 145 (62)| 1.00 (ref)     |         | 1.00 (ref)      |         |
| ≤14                                  | 89 (38)| 3.58 (1.72–7.49)| <0.001 | 1.55 (1.04–2.31)| 0.032   |
| Variable                        | No. (%) | OS HR (95% CI) | p-Value | rPFS HR (95% CI) | p-Value |
|--------------------------------|---------|----------------|---------|-----------------|---------|
| IADL, median                   |         |                |         |                 |         |
| >6                             | 121 (52)| 1.00 (ref)     | 1.00 (ref) |                 |         |
| ≤6                             | 113 (48)| 1.60 (0.88–2.91) | 0.123 | 1.11 (0.76–1.63) | 0.576 |
| Concomitant therapies, no.     |         |                |         |                 |         |
| ≥3                             | 132 (56)| 1.00 (ref)     | 1.00 (ref) |                 |         |
| <3                             | 102 (44)| 1.07 (0.60–1.93) | 0.815 | 0.89 (0.61–1.31) | 0.550 |
| Caregiver                      |         |                |         |                 |         |
| Yes                            | 190 (81)| 1.00 (ref)     | 1.00 (ref) |                 |         |
| No                             | 44 (19) | 0.46 (0.18–1.16) | 0.098 | 0.57 (0.32–0.99) | **0.047** |
| Treatment                      |         |                |         |                 |         |
| Enza                           | 148 (63)| 1.00 (ref)     | 1.00 (ref) |                 |         |
| Abi                            | 86 (37) | 0.74 (0.40–1.36) | 0.329 | 0.65 (0.43–0.99) | **0.042** |
| PSA50                          |         |                |         |                 |         |
| No                             | 65 (28) | 1.00 (ref)     | 1.00 (ref) |                 |         |
| Yes                            | 164 (71)| 0.18 (0.10–0.32) | **<0.001** | 0.25 (0.17–0.37) | **<0.001** |
| Toxicity, G1/G2                |         |                |         |                 |         |
| No                             | 100 (43)| 1.00 (ref)     | 1.00 (ref) |                 |         |
| Yes                            | 134 (57)| 1.58 (0.83–2.99) | 0.164 | 1.07 (0.72–1.59) | 0.732 |
| Toxicity, G3/G4                |         |                |         |                 |         |
| No                             | 222 (95)| 1.00 (ref)     | 1.00 (ref) |                 |         |
| Yes                            | 12 (5)  | 2.53 (0.90–7.08) | 0.077 | 1.88 (0.87–4.07) | 0.107 |

* At the time of initiation of treatment. b During the whole treatment. Abi, abiraterone; CI, confidence intervals; CR, castration resistance; Enza, enzalutamide; FU, follow-up; mo., months; G, grade; NA, not assessable; No., number; OS, overall survival; PSA50, decline in the PSA ≥ 50%; ref, reference; rPFS, radiographic progression-free survival; Tx, treatment. Statistically significant values in bold (p < 0.005).
Table 2. Cox regression multivariable analysis of clinical baseline and on-treatment prognostic factors.

| Variable                                | OS HR (95% CI) | p-Value | rPFS HR (95% CI) | p-Value |
|-----------------------------------------|----------------|---------|-----------------|---------|
| Age a, median, years                    |                |         |                 |         |
| <78                                     | 1.00 (ref)     |         |                 |         |
| ≥78                                     | 2.47 (1.27–4.79)| 0.008   |                 |         |
| Geriatric G8, median                    |                |         |                 |         |
| >14                                     | 1.00 (ref)     |         | 1.00 (ref)      |         |
| ≤14                                     | 3.10 (1.43–6.74)| 0.004   | 2.39 (1.46–3.91)| <0.001 |
| PSA50                                   |                |         |                 |         |
| No                                      | 1.00 (ref)     |         | 1.00 (ref)      |         |
| Yes                                     | 0.14 (0.07–0.25)| <0.001 | 0.29 (0.18–0.46)| <0.001 |
| Gleason score, median                   |                |         |                 |         |
| ≥8                                      | 1.00 (ref)     |         | 0.82 (0.49–1.38)| 0.457   |
| <8                                      |                |         | 1.00 (ref)      |         |
| Surgery at diagnosis                    |                |         |                 |         |
| Yes                                     |                |         | 1.38 (0.87–2.21)| 0.173   |
| No                                      |                |         |                 |         |
| Time to CR, mo, median                  |                |         | 1.00 (ref)      |         |
| <31                                     |                |         | 2.30 (1.46–3.64)| <0.001 |
| ≥31                                     |                |         |                 |         |
| Sites of metastases a                   |                |         |                 |         |
| Bone (non-visceral)                     | 1.00 (ref)     |         |                 |         |
| Lymph nodes (only)                      | 0.51 (0.23–1.11)| 0.459 |                 |         |
| Visceral                                | 0.90 (0.46–1.76)| 0.748 |                 |         |
| Setting of therapy                      |                |         |                 |         |
| Post-chemotherapy                       | 1.00 (ref)     |         |                 |         |
| Pre-chemotherapy                        | 0.69 (0.42–1.15)| 0.157 |                 |         |
| Post-Abi/Enza                           | 4.31 (1.42–13.04)| 0.010 |                 |         |
| Charlson score, median                  |                |         | 1.00 (ref)      |         |
| ≥9                                      |                |         | 0.61 (0.34–1.11)| 0.109   |
| <9                                      |                |         |                 |         |
| Caregiver                               |                |         |                 |         |
| Yes                                     |                |         |                 |         |
| No                                      | 0.69 (0.36–1.31)| 0.251 |                 |         |
| Treatment                               |                |         |                 |         |
| Enza                                    | 1.00 (ref)     |         | 0.75 (0.46–1.19)| 0.221   |
| Abi                                     |                |         |                 |         |

Abbreviations: Abi, abiraterone; BM, bone metastases (non-visceral); ChT, chemotherapy; CI, confidence intervals; CR, castration resistance; Enza, enzalutamide; HR, hazard ratio; LN, lymphnodes; No. Number; OS, overall survival; PSA50, decline in the PSA ≥ 50%; ref, reference; rPFS, radiographic progression-free survival; Tx, treatment. a Only for variables with a p-value < 0.05 at univariable analysis. Statistically significant values in bold (p < 0.005).

4. Discussion

Frailty is a complex interplay of illness and health, personal attitudes, reliance on others, and resources [13]. Therefore, CGA, which explores comorbidities, mental health and cognitive status, functional status, nutrition, social status and support, polypharmacy, and geriatric syndromes, represents the perfect tool to assess such a multifaceted condition as frailty in older cancer patients [14,15].

The aim of CGA is to identify patients who need optimization of medical treatments, thus improving their prognosis, by restoring autonomy or, where possible, supporting its loss to ameliorate overall patients’ quality of life [16]. However, the CGA is time-consuming, implies the presence of geriatric team, and has too many elements that need to be tested, making its use unsuitable for many oncology centers [17].

International medical societies, like the European Organization for Research and Treatment of Cancer (EORTC), European Association of Urology (EAU) and International Society of Geriatric Oncology (SIOG), all recommend screening cancer patients aged ≥ 70 with the
G8 since this was proven to identify those requiring a more complex CGA [7]. Nevertheless, as emerged in recent surveys, up to half of the clinicians use merely the performance status (PS) by Karnofsky (KPS) or Eastern Cooperative Oncology Group (ECOG PS) scores to assess patient’s frailty and select older patients for chemotherapy [18–20]. Unfortunately, these scores consider physical functioning only, neglecting psychosocial, nutritional and cognitive aspects, which are crucial to evaluating patient’s frailty status [21].

In addition, nearly 40% of the physicians admit to ignoring the G8 scale, and only 50% declare to use it in clinical practice, without apparent regional differences [22].

Moreover, recommendations for using the G8 score from international guidelines were extended to older PC patients without ad hoc prospective studies. By the present study, which focused on older patients with mCRPC treated with ARPIs, we could confirm the relevance of geriatric assessment and G8 as a reliable screening tool. In this setting, G8 can select patients who deserve comprehensive geriatric assessment (CGA) to identify frail or vulnerable patients. As suggested by the International Society of Geriatric Oncology (SIOG) [3], best supportive care (BSC) remains the preferred option for the former. Conversely, treatment for vulnerable patients carrying reversible clinical conditions should be considered, including the early introduction of palliative care.

While PSA responses have been invariably associated with PFS and OS on hormonal treatments, without satisfying Prentice’s criteria for surrogacy [23], to the best of our knowledge, this is the first prospective study aiming to evaluate the G8 screening in mCRPC and showing its correlation with rPFS and OS. In the ADHERE study, we could not demonstrate an association between a reduced adherence to ARPIs and rPFS or OS, although the G8 was significantly linked to treatment adherence [10]. Therefore, we reckon that the reduced OS and rPFS of patients with a G8 score > 14 likely mirror the general health status as demonstrated in other cancer patients.

The results presented here, however, do not derive from a pre-planned analysis and lack internal or external validation. Furthermore, a higher number of events would have improved the accuracy of the UVA and MVA estimates, despite the median follow-up being adequate in metastatic castrate-resistant prostate setting. These represent the main limitations of our work.

5. Conclusions

Our analysis shows that, in a prospective observational study on older mCRPC patients treated with ARPIs, G8 screening is a baseline prognostic factor for rPFS and OS. Therefore, we envision that G8 will become a baseline screening tool for treatment decisions, as already recommended by international guidelines.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/curroncol29100612/s1, Table S1: Patient characteristics in the whole ADHERE study cohort and by ARPI. Figure S1: Histogram of distribution of patients based on Geriatric G8 score.

Author Contributions: Conception/Design: G.L.B., G.F. and U.B. Provision of study material or patients: M.M., S.E.R., M.C., H.L., L.F., T.G., D.B., A.D. and P.E. Collection and/or assembly of data: Aichi Msaki, V.M., B.B., V.L. and F.V. Data analysis and interpretation: G.L.B., P.R., O.C., Alessandra Mosca, E.F.G., V.C., U.D.G. and S.B. Manuscript writing: P.R. and G.L.B. Final approval of manuscript: all authors. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was approved by the Catania-1 ethical committee (n.12/2019/CA of the 15th of February 2019). The study was performed in accordance with the Good Clinical Practice guidelines of the International Conference on Harmonization and the Declaration of Helsinki.

Informed Consent Statement: All patients provided the protocol written informed consent.
Data Availability Statement: The datasets generated and analysed during the current study are not publicly available as they are part of the confidential medical record but are available from the corresponding author on reasonable request.

Acknowledgments: S.E.R. and G.F. would like to thank the Italian Ministry of Health (Ricerca Corrente 2018–2021 grants), which financially supports their current research on identifying prognostic and predictive markers for patients with genitourinary tumors. P.R.’s work is funded by Prostate Cancer Foundation through a PCF Y1 award and by the FPRC 5 PER MILLE—Ministero della Salute 2017—PTCRC SEE PROS ONCOLOGIA and “Italian Ministry of Health, Ricerca Corrente 2022”. G.L.B.’s work is supported by FPRC 5ximille Ministero Salute 2017 PTCRC-Intra 2020 “CTU-Lung”.

Conflicts of Interest: P.R. has served as a consultant/advisory board member for MSD and Astra Zeneca. V.C. has served as a consultant/advisory board member for Janssen, Astellas, Merck, AstraZeneca and Bayer and has received speaker honoraria or travel support from Astellas, Janssen, Ipsen, Bayer. S.E.R. has received honoraria as a speaker at scientific events and travel accommodation from Amgen, GSK, BMS, MSD. G.F. has been a consultant for Astellas, Janssen, Pfizer, Bayer, MSD, Merck and received travel accommodation from Astellas, Janssen, Bayer. U.D.G. received honoraria for advisory boards or speaker fees for Pfizer, BMS, MSD, PharmaMar, Astellas, Bayer, Ipsen, Roche, Novartis, Clovis, GSK, AstraZeneca, institutional research grants from AstraZeneca, Sanofi and Roche. D.B. received personal fees for Talks or Advisory/Consultant Role from Ipsen, Astellas, Janssen, Novartis, BMS, MSD outside the submitted work. O.C. ADVISOR: AAA, Astra Zeneca, Astellas, Bayer, Janssen, Ipsen, MSD, Pfizer Speaker: Ipsen, MSD, Astra Zeneca, Astellas, Janssen. G.L.B. reported personal fees from Astellas and AstraZeneca.

References
1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2018, 68, 394–424. [CrossRef]
2. Wong, M.C.; Goggins, W.B.; Wang, H.H.; Fung, F.D.; Leung, C.; Wong, S.Y.; Ng, C.F.; Sung, J.J. Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries. Eur. Urol. 2016, 70, 862–874. [CrossRef]
3. Boyle, H.J.; Alibhai, S.; Decoster, L.; Efstathiou, E.; Fizazi, K.; Mottet, N.; Oudard, S.; Payne, H.; Prentice, M.; Puts, M.; et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur. J. Cancer 2019, 116, 116–136. [CrossRef] [PubMed]
4. Droz, J.P.; Balducci, L.; Bolla, M.; Emberton, M.; Fitzpatrick, J.M.; Joniau, S.; Kattan, M.W.; Monfardini, S.; Moul, J.W.; Naeim, A.; et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit. Rev. Oncol. Hematol. 2010, 73, 68–91. [CrossRef] [PubMed]
5. Giunta, E.F.; Annaratone, L.; Bollito, E.; Porpiglia, F.; Cereda, M.; Banna, G.L.; Mosca, A.; Marchiò, C.; Ruscigno, P. Molecular Characterization of Prostate Cancers in the Precision Medicine Era. Cancers 2021, 13, 4771. [CrossRef] [PubMed]
6. Droz, J.P.; Albrand, G.; Gilleszen, S.; Hughes, S.; Mottet, N.; Oudard, S.; Payne, H.; Puts, M.; Zulian, G.; Balducci, L.; et al. Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. Eur. Urol. 2017, 72, 521–531. [CrossRef]
7. Soubeyran, P.; Bellera, C.; Goyard, J.; Heitz, D.; Curé, H.; Rousselot, H.; Albrand, G.; Servent, V.; Jean, O.S.; van Praagh, I.; et al. Screening for vulnerability in older cancer patients: The ONCODAGE Prospective Multicenter Cohort Study. PLoS ONE 2014, 9, e115060. [CrossRef] [PubMed]
8. Banna, G.L.; Urzia, V.; Benanti, C.; Pitrè, A.; Lipari, H.; Di Quattro, R.; De Giorgi, U.; Schepisi, G.; Basso, U.; Bimbatti, D.; et al. Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. Support. Care Cancer 2020, 28, 4687–4695. [CrossRef] [PubMed]
9. Banna, G.L.; Collovà, E.; Gebbia, V.; Lipari, H.; Giuffrida, P.; Cavallaro, S.; Condorelli, R.; Buscarino, C.; Tralongo, P.; Ferraiu, F. Anticancer oral therapy: Emerging related issues. Cancer Treat. Rev. 2010, 36, 595–605. [CrossRef] [PubMed]
10. Ruscigno, P.; Maruzzo, M.; Cinausero, M.; Lipari, H.; Fratino, L.; Gamba, T.; De Giorgi, U.; Caffo, O.; et al. Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network. Oncologist 2022, [CrossRef] [PubMed]
11. Charlson, M.; Szatrowski, T.P.; Peterson, J.; Gold, J. Validation of a combined comorbidity index. J. Clin. Epidemiol. 1994, 47, 1245–1251. [CrossRef]
12. Wenzel, M.; Preissler, F.; Hoeb, B.; Schroeder, M.; Würnschimmel, C.; Steuber, T.; Heinzner, H.; Banek, S.; Ahrens, M.; Becker, A.; et al. Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies. Front. Oncol. 2021, 11, 659135. [CrossRef] [PubMed]
13. Rockwood, K.; Fox, R.A.; Stolee, P.; Robertson, D.; Beattie, B.L. Frailty in elderly people: An evolving concept. CMAJ 1994, 150, 489–495. [PubMed]
14. Wildiers, H.; Heeren, P.; Puts, M.; Topinkova, E.; Janssen-Heijnen, M.L.; Extermann, M.; Falandry, C.; Artz, A.; Brain, E.; Colloca, G.; et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. *J. Clin. Oncol.* 2014, 32, 2595–2603. [CrossRef]

15. Decoster, L.; Van Puyvelde, K.; Mobile, S.; Wedding, U.; Basso, U.; Colloca, G.; Rostoft, S.; Overcash, J.; Wildiers, H.; Steer, C.; et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: An update on SIOG recommendations. *Ann. Oncol.* 2015, 26, 288–300. [CrossRef] [PubMed]

16. Bernabei, R.; Venturiero, V.; Tarsitani, P.; Gambassi, G. The comprehensive geriatric assessment: When, where, how. *Crit. Rev. Oncol. Hematol.* 2000, 33, 45–56.

17. Ethun, C.G.; Bilen, M.A.; Jani, A.B.; Maithel, S.K.; Ogan, K.; Master, V.A. Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology. *CA A Cancer J. Clin.* 2017, 67, 362–377. [CrossRef]

18. Zereshkian, A.; Cao, X.; Puts, M.; Dawdy, K.; Di Prospero, L.; Alibhai, S.; Neve, M.; Szumacher, E. Do Canadian Radiation Oncologists Consider Geriatric Assessment in the Decision-Making Process for Treatment of Patients 80 years and Older with Non-Metastatic Prostate Cancer?-National Survey. *J Geriatr. Oncol.* 2019, 10, 659–665. [CrossRef]

19. To, T.H.; Soo, W.K.; Lane, H.; Khattak, A.; Steer, C.; Devitt, B.; Dhillon, H.M.; Booms, A.; Phillips, J. Utilisation of geriatric assessment in oncology—a survey of Australian medical oncologists. *J Geriatr. Oncol.* 2019, 10, 216–221. [CrossRef]

20. Moth, E.B.; Kiely, B.E.; Naganathan, V.; Martin, A.; Blinman, P. How do oncologists make decisions about chemotherapy for their older patients with cancer? A survey of Australian oncologists. *Support. Care Cancer* 2018, 26, 451–460. [CrossRef]

21. van Walree, I.C.; Scheepers, E.R.M.; van den Bos, F.; van Huis-Tanja, L.H.; Emmelot-Vonk, M.H.; Hamaker, M.E. Clinical judgment versus geriatric assessment for frailty in older patients with cancer. *J Geriatr. Oncol.* 2020, 11, 1138–1144. [PubMed]

22. Baldini, C.; Brain, E.G.C.; Rostoft, S.; Biganzoli, L.; Goede, V.; Kanesvaran, R.; Quoix, E.; Steer, C.; Papamichael, D.; Wildiers, H. 1827P European Society for Medical Oncology (ESMO)/International Society of Geriatric Oncology (SIOG) Joint Working Group (WG) survey on management of older patients with cancer. *Ann. Oncol.* 2021, 32, S1237–S1238. [CrossRef]

23. Rescigno, P.; Dolling, D.; Conteduca, V.; Rediti, M.; Bianchini, D.; Lolli, C.; Ong, M.; Li, H.; Omlin, A.G.; Schmid, S.; et al. Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. *Eur. Urol. Oncol.* 2020, 3, 176–182. [CrossRef] [PubMed]